Drug Profile
Cridanimod - Pharmsynthez/Xenetic Biosciences
Alternative Names: Sodium cridanimod; Virexxa; XBIO-101Latest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Pharmsynthez
- Developer AS Kevelt; Pharmsynthez; Xenetic Biosciences
- Class Acetic acids; Acridines; Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; Interferon stimulants; Progesterone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Endometrial cancer; Triple negative breast cancer
Most Recent Events
- 07 Sep 2022 Discontinued - Phase-II for Endometrial cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Belarus, Ukraine, Slovakia, Czech Republic, USA (IM)
- 07 Sep 2022 Discontinued - Phase-II for Endometrial cancer (Late-stage disease, Second-line therapy or greater) in Russia (IM)
- 07 Sep 2022 Discontinued - Preclinical for Triple-negative-breast cancer in USA (unspecified route)